Drug Trial Radar · NCT05306132
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067
Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Aug 8, 2022
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is the first-in-human of ASKC202, which is an open-label, non-randomized, multicenter study with a dose escalation phase and a dose expansion phase.
Conditions
- Advanced Solid Tumor
Interventions
ASKC202Drug
Dosage Forms: Tablets; Administration: Oral administration
ASK120067Drug
Dosage Forms: Tablets; Administration: Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and case number of DLT (Dose Limiting Toxicity) during observation periodTime frame: up to 21 days following first dose
- Maximum Tolerated Dose (MTD)Time frame: up to 21 days following first dose
- Number of participants with adverse events and serious adverse events as assessed by CTCAE v5.0Time frame: up to 30 days following last dose
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Xiangya Hospital Central South University
Changsha, Hunan, China · Recruiting
Shanghai East Hospital Affiliated to Tongji University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.